WallStreetZenWallStreetZen

NASDAQ: TECX
Tectonic Therapeutic Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Analyst price target for TECX

Based on 2 analysts offering 12 month price targets for Tectonic Therapeutic Inc

Min Forecast
$60.00+194.55%
Avg Forecast
$70.00+243.64%
Max Forecast
$80.00+292.73%

Should I buy or sell TECX stock?

Based on 2 analysts offering ratings for Tectonic Therapeutic Inc.

Strong Buy
Strong Buy
1 analysts 50%
Buy
1 analysts 50%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%
Although TECX's forecast from analysts indicates a "Strong Buy", our proven Zen Rating quant model rates TECX as a "Strong Sell". Stocks with a Zen Rating of Strong Sell have had an average return of -8.02% per year. Learn More

Be the first to know when Wall Street analysts revise their TECX stock forecasts and price targets.

TECX stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2026-01-08
lockedlocked$00.00+00.00%2025-09-03

1 of 1

Forecast return on equity

Is TECX forecast to generate an efficient return?

Company
-37.74%
Industry
91.77%
Market
361.52%
TECX's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is TECX forecast to generate an efficient return on assets?

Company
-36.45%
Industry
27.9%
TECX is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

TECX earnings per share forecast

What is TECX's earnings per share in the next 2 years based on estimates from 11 analysts?

Avg 1 year Forecast
-$4.85
Avg 2 year Forecast
-$5.39

TECX revenue forecast

What is TECX's revenue in the next 2 years based on estimates from 11 analysts?

Avg 1 year Forecast
$0.0
Avg 2 year Forecast
$0.0

TECX vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
TECX$20.37$70.00+243.64%Strong Buy
AUTL$1.42$7.50+428.17%Strong Buy
PEPG$5.60$11.50+105.36%Strong Buy
LCTX$1.63$5.50+237.42%Strong Buy
ENTA$12.98$20.40+57.16%Strong Buy
View Top Biotech Stocks

Tectonic Therapeutic Stock Forecast FAQ

Is Tectonic Therapeutic Stock a good buy in 2026, according to Wall Street analysts?

The consensus among 2 Wall Street analysts covering (NASDAQ: TECX) stock is to Strong Buy TECX stock.

Out of 2 analysts, 1 (50%) are recommending TECX as a Strong Buy, 1 (50%) are recommending TECX as a Buy, 0 (0%) are recommending TECX as a Hold, 0 (0%) are recommending TECX as a Sell, and 0 (0%) are recommending TECX as a Strong Sell.

If you're new to stock investing, here's how to buy Tectonic Therapeutic stock.

What is TECX's earnings growth forecast for 2026-2027?

(NASDAQ: TECX) Tectonic Therapeutic's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 205.31%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 3,309.49%.

Tectonic Therapeutic's earnings in 2026 is -$67,298,000.On average, 11 Wall Street analysts forecast TECX's earnings for 2026 to be -$90,734,654, with the lowest TECX earnings forecast at -$99,963,651, and the highest TECX earnings forecast at -$75,464,041.

In 2027, TECX is forecast to generate -$100,957,486 in earnings, with the lowest earnings forecast at -$133,162,589 and the highest earnings forecast at -$78,608,376.

What is TECX's revenue growth forecast for 2026-2027?

(NASDAQ: TECX) Tectonic Therapeutic's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 12,072.72%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 1,611.96%.

Tectonic Therapeutic's revenue in 2026 is $0.On average, 11 Wall Street analysts forecast TECX's revenue for 2026 to be $0, with the lowest TECX revenue forecast at $0, and the highest TECX revenue forecast at $0.

In 2027, TECX is forecast to generate $0 in revenue, with the lowest revenue forecast at $0 and the highest revenue forecast at $0.

What is TECX's forecast return on assets (ROA) for 2026-2027?

(NASDAQ: TECX) forecast ROA is -36.45%, which is lower than the forecast US Biotechnology industry average of 27.9%.

What is TECX's Price Target?

According to 2 Wall Street analysts that have issued a 1 year TECX price target, the average TECX price target is $70.00, with the highest TECX stock price forecast at $80.00 and the lowest TECX stock price forecast at $60.00.

On average, Wall Street analysts predict that Tectonic Therapeutic's share price could reach $70.00 by Jan 8, 2027. The average Tectonic Therapeutic stock price prediction forecasts a potential upside of 243.64% from the current TECX share price of $20.37.

What is TECX's Earnings Per Share (EPS) forecast for 2026-2027?

(NASDAQ: TECX) Tectonic Therapeutic's current Earnings Per Share (EPS) is -$2.69. On average, analysts forecast that TECX's EPS will be -$4.85 for 2026, with the lowest EPS forecast at -$5.34, and the highest EPS forecast at -$4.03. In 2027, TECX's EPS is forecast to hit -$5.39 (min: -$7.11, max: -$4.20).

What is TECX's forecast return on equity (ROE) for 2026-2027?

(NASDAQ: TECX) forecast ROE is -37.74%, which is considered weak.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.